Applications of Desoxycorticosterone Pivalate in Industrial Manufacturing

Desoxycorticosterone Pivalate serves as a specialized corticosteroid raw material primarily adopted by the pharmaceutical sector for specific hormone therapies and diagnostic preparations. Our production process ensures consistency and traceability, allowing reliable downstream integration for regulated industrial and medical applications. This overview details the practical implementation in select manufacturing contexts where the material has proven records of real-world utility.

1. Injectable Veterinary Hormone Preparations

Veterinary pharmaceutical formulators use Desoxycorticosterone Pivalate extensively in the production of injectable mineralocorticoid therapies for managing Addison’s disease (hypoadrenocorticism) in dogs and other companion animals. This steroid ester is prized for its long-acting properties, favoring monthly or bi-monthly dosing schedules. Commercially, manufacturers must ensure precise homogenization during suspension formulation and uphold stringent QA standards due to the injectable route and animal health end use.

Industry compliance standards

• US FDA Center for Veterinary Medicine (CVM) guidelines
• European Pharmacopoeia (Ph. Eur.) monograph standards (where applicable)
• Good Manufacturing Practice for Veterinary Medicinal Products (VMP-GMP)
• VICH GL3 stability requirements

Typical usage ratio

• 1%–4% by weight in aqueous/oily injectable suspensions, dosage adjusted according to final concentration (commonly 25mg/ml final product strength); required ratio varies by animal species and intended dosing interval.

Downstream process integration

• Weighing and pre-milling for particle size uniformity
• Dispersal into sterile vehicle under controlled temperature and agitation
• Sterile filtration followed by aseptic filling into vials or ampoules

Final product types

• Veterinary injectable suspensions (e.g., for canine Addison’s disease)
• Single and multi-dose vials for animal clinics

2. Human Steroid Hormone Research Standards

Biopharmaceutical companies and laboratory reagent producers incorporate Desoxycorticosterone Pivalate into analytical reagent kits and as certified reference materials for endocrinology research. Its stable ester form provides reliable calibration for LC-MS/MS and immunoassay methods, especially in hormone profiling and pharmacokinetics studies. Downstream processes require rigorous documentation and validation of identity and purity, with complete traceability for audit trails.

Industry compliance standards

• ISO 17034 Reference Material Producer accreditation
• FDA 21 CFR Part 820 (Quality System Regulation for Medical Devices, applicable to diagnostics)
• United States Pharmacopeia (USP) reference standard criteria
• OECD Good Laboratory Practice (GLP)

Typical usage ratio

• 0.01%–0.1% by weight for calibration solutions; Specific gravimetric additions are set according to target analytical range and batch size.

Downstream process integration

• Primary weighing and dissolution in defined analytical solvents under controlled conditions
• Aliquoting into labeled ampoules or vials
• Batchwise homogeneity testing and certificate of analysis (CoA) generation

Final product types

• Certified reference standards for clinical laboratories
• Hormone metabolite panel kits for mass spectrometry
• Quality control materials for endocrinology assay developers

3. Pharmaceutical Formulation of Sustained-release Mineralocorticoid Implants (Animal Use)

Veterinary drug developers utilize Desoxycorticosterone Pivalate in the design of long-acting subcutaneous implants to deliver controlled mineralocorticoid levels in livestock and laboratory animals. These slow-release formats require precise ingredient blending with biocompatible matrix materials, as well as validated extrusion or compression technologies. Production lines implementing this raw material must maintain tight control over uniformity and in vitro release profiles.

Industry compliance standards

• OECD Principles of Good Manufacturing Practice
• European Medicines Agency (EMA) guidelines on sustained-release veterinary formulations
• Specific Maximum Residue Limits (MRLs) for food-producing animals
• USP <797> Sterile Compounding (for extemporaneous preparations, where local regulations apply)

Typical usage ratio

• 10%–20% by weight of total implant matrix, set according to designed release kinetics and dosing requirements for animal size and species.

Downstream process integration

• Integration with biodegradable polymers by high-shear blending
• Hot-melt extrusion or cold compression into rod or pellet format
• Packaging under aseptic or controlled environmental conditions

Final product types

• Implantable drug delivery systems for veterinary care
• Pre-loaded applicators for controlled-release hormone administration

4. Synthesis of Corticosteroid Ester Intermediates

Chemical and pharmaceutical synthesis companies employ Desoxycorticosterone Pivalate as a key intermediate for further derivatization or for structural modification studies. The pivalate ester group ensures both stability and selective deprotection during multi-step synthesis routes used in developing novel corticosteroid analogs or prodrugs. Integration into production occurs under cGMP protocols in pilot or commercial-scale manufacturing.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU Directive 2001/83/EC on medicines for human use (for active intermediates)
• ISO 9001:2015 Quality Management System
• Local Health Authority (LHA) site inspection requirements

Typical usage ratio

• Scale-dependent stoichiometric quantities; typically 0.5–1.5 equivalents per batch in esterification or transesterification steps, adjusted based on reaction scale and yield optimization.

Downstream process integration

• Charging into reactor vessels with ancillary reagents for further chemical modification
• Solvent extraction and isolation via crystallization or chromatography
• Analytical testing for intermediate verification and release

Final product types

• Downstream corticosteroid chemical intermediates
• Novel hormone prodrugs for further clinical development